Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer

N-myc downstream-regulated gene 2 (NDRG2) is a tumor suppressor and cell stress-related gene. NDRG2 is associated with tumor incidence, progression, and metastasis. NDRG2 regulates tumor-associated genes and is regulated by multiple conditions, treatments, and protein/RNA entities, including hyperth...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-01, Vol.7 (1), p.209-223
Main Authors: Hu, Wei, Fan, Chongxi, Jiang, Peng, Ma, Zhiqiang, Yan, Xiaolong, Di, Shouyin, Jiang, Shuai, Li, Tian, Cheng, Yedong, Yang, Yang
Format: Article
Language:English
Subjects:
Apoptosis - genetics
Cell Proliferation - genetics
Gene Expression Regulation, Neoplastic
Humans
Models, Genetic
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Review
Signal Transduction - genetics
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:N-myc downstream-regulated gene 2 (NDRG2) is a tumor suppressor and cell stress-related gene. NDRG2 is associated with tumor incidence, progression, and metastasis. NDRG2 regulates tumor-associated genes and is regulated by multiple conditions, treatments, and protein/RNA entities, including hyperthermia, trichostatin A and 5-aza-2'-deoxycytidine, which are promising potential cancer therapeutics. In this review, we discuss the expression as well as the clinical and pathological significance of NDRG2 in cancer. The pathological processes and molecular pathways regulated by NDRG2 are also summarized. Moreover, mechanisms for increasing NDRG2 expression in tumors and the potential directions of future NDRG2 research are discussed. The information reviewed here should assist in experimental design and increase the potential of NDRG2 as a therapeutic target for cancer.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.6228